Complementary therapies in clinical practice · 2025
Optimal exercise dosage and type for improving post-traumatic stress disorder: a systematic review and network meta-analysis of randomized controlled trials.
СтатьяСистематический обзорNetwork Meta-AnalysisНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xiong-Jie, Xia Han, Yu Guang-Hui, Hu Yi-Xin, Zhu Fei-Long
Аннотация
OBJECTIVE: Post-traumatic stress disorder (PTSD) is a debilitating mental health condition. Emerging evidence suggests exercise may be effective in alleviating PTSD symptoms. This systematic review and network meta-analysis aimed to identify the most effective types and dosages of exercise for managing PTSD in adults.
METHODS: A systematic search of six databases (PubMed, Embase, Web of Science, SPORTDiscus, Scopus, PsycINFO) through November 2024 identified randomized controlled trials involving adults with PTSD. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were calculated. The GRADE framework was used to assess evidence certainty.
RESULTS: Thirty randomized controlled trials involving 1435 participants were included. An inverted U-shaped dose-response relationship was found between exercise dosage and PTSD symptom reduction, with the greatest effect at ∼730 Metabolic Equivalent of Task minutes per week (SMD = 0.53; 95 % CI: 0.28-0.82). Multicomponent exercise showed the strongest benefits. Optimal outcomes were linked to 30-min sessions, more than four times per week, at moderate-to-vigorous intensity.
CONCLUSION: Exercise exerted a non-linear dose-response effect on post-traumatic stress disorder symptoms, with optimal benefits observed at approximately 730 Metabolic Equivalent of Task minutes per week. Meanwhile, multicomponent exercise was identified as the most effective modality. Short-duration, high-frequency, high-intensity regimens yielded the greatest improvements. However, the overall current certainty of the evidence was moderate-to-low due to heterogeneity among studies. Therefore, further high-quality trials are necessitated to establish optimal doses, exercise types, and individual variability in response.
REGISTRATION: PROSPERO (CRD4202412345111).
METHODS: A systematic search of six databases (PubMed, Embase, Web of Science, SPORTDiscus, Scopus, PsycINFO) through November 2024 identified randomized controlled trials involving adults with PTSD. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were calculated. The GRADE framework was used to assess evidence certainty.
RESULTS: Thirty randomized controlled trials involving 1435 participants were included. An inverted U-shaped dose-response relationship was found between exercise dosage and PTSD symptom reduction, with the greatest effect at ∼730 Metabolic Equivalent of Task minutes per week (SMD = 0.53; 95 % CI: 0.28-0.82). Multicomponent exercise showed the strongest benefits. Optimal outcomes were linked to 30-min sessions, more than four times per week, at moderate-to-vigorous intensity.
CONCLUSION: Exercise exerted a non-linear dose-response effect on post-traumatic stress disorder symptoms, with optimal benefits observed at approximately 730 Metabolic Equivalent of Task minutes per week. Meanwhile, multicomponent exercise was identified as the most effective modality. Short-duration, high-frequency, high-intensity regimens yielded the greatest improvements. However, the overall current certainty of the evidence was moderate-to-low due to heterogeneity among studies. Therefore, further high-quality trials are necessitated to establish optimal doses, exercise types, and individual variability in response.
REGISTRATION: PROSPERO (CRD4202412345111).